|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.980 EUR | -1.00% |
|
-1.00% | -1.00% |
| 06-30 | Neovacs bolsters its strategic intellectual property portfolio |  |
| 02-10 | Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted | CI |
Company Valuation: NEOVACS
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Market Cap 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Enterprise Value (EV) 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| P/E | -96,912,987x | -264,999,452x | -6,728x | -22,860,253x | - | - |
| PBR | - | - | - | - | - | - |
| PEG | - | 3,273,301.5x | -0x | 229,169x | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.0479 | -0.009117 | -5.946 | -0.0147 | - | - |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.0952 | 0.031 | 0.0225 | 0.001112 | 0.5334 | 0.4339 |
| EBITDA 1 | -8.118 | -3.437 | -7.728 | -6.294 | -6.06 | -6.43 |
| EBIT 1 | -8.175 | -3.492 | -7.828 | -6.445 | -6.908 | -6.622 |
| Net income 1 | -7.548 | -6.143 | -11.84 | -3.549 | -8.743 | -32.91 |
| Net Debt 1 | -1.234 | -9.681 | -32.06 | -5.555 | -0.2365 | -0.2051 |
| Reference price 2 | 4,640,000.000 | 2,416,000.000 | 40,000.000 | 336,000.000 | 20,000.000 | 10,212,000.000 |
| Nbr of stocks (in thousands) | - | - | - | - | - | - |
| Announcement Date | 4/30/20 | 6/29/21 | 5/2/22 | 4/30/23 | 4/30/24 | 4/30/25 |
1EUR in Million2EUR
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 34.53x | 6.07x | 18.77x | 0.95% | 49.74B | |
| -23.85x | 349.22x | -22.56x | -.--% | 40.49B | |
| 25.34x | 2.8x | 12.11x | -.--% | 34.75B | |
| 47.3x | 4.68x | 29.91x | -.--% | 34.35B | |
| 27.63x | 7.94x | 19.87x | 0.41% | 26.98B | |
| 32.22x | 5.2x | 23.7x | -.--% | 15.6B | |
| -24.06x | 15.69x | -23.46x | -.--% | 14.27B | |
| 23.93x | 2.04x | 8.96x | 1.12% | 13.76B | |
| Average | 17.88x | 49.20x | 8.41x | 0.31% | 28.74B | |
| Weighted average by Cap. | 19.53x | 66.31x | 9.41x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALNEV Stock
- ALNEV Stock
- Valuation NEOVACS
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
